The Mayo Nephrology Collaborative Group (MNCG) develops and conducts studies of renal parenchymal diseases, including membranous nephropathy. The MNCG is a consortium of nephrologists from Mayo Clinic campuses in Minnesota, Florida and Arizona and from other centers across the United States.
Mayo Clinic has conducted clinical studies evaluating the feasibility and effectiveness of rituximab (Rituxan) in treating membranous nephropathy. A randomized trial comparing the drug with calcineurin inhibitors (cyclosporine and tacrolimus) is planned. Mayo researchers are also studying the role of a variety of antibodies in membranous nephropathy.
Mayo is also evaluating the use of adrenocorticotropic hormone (ACTH) in the treatment of membranous nephropathy. Recent European studies have shown that treatment with synthetic ACTH is highly effective in reducing proteinuria in people who have membranous nephropathy with minimal side effects. Mayo is looking to confirm these findings in U.S. patients.
See a list of publications on membranous nephropathy by Mayo doctors on PubMed.